{"id":"W3199546106","doi":"10.1016/s1474-4422(21)00242-8","title":"Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial","year":2021,"lang":"en","type":"letter","venue":"The Lancet Neurology","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"National Institute for Health and Care Research; OMRON Corporation","keywords":"Medicine; Amyotrophic lateral sclerosis; Clinical endpoint; Placebo; Levosimendan; Adverse effect; Population; Internal medicine; Physical therapy; Riluzole; Clinical trial; Heart failure; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002359564,0.0006598925,0.004072428,0.000296012,0.0002054506,0.00008548128,0.00075813,0.0006359591,0.0002807152],"category_scores_gemma":[0.0003026891,0.0003248173,0.0003243828,0.0006591793,0.0006627423,0.0000681674,0.0003936058,0.004557712,0.00001131153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007277476,"about_ca_system_score_gemma":0.000340282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007285379,"about_ca_topic_score_gemma":0.0005288515,"domain_scores_codex":[0.9920191,0.003620021,0.001278889,0.00100359,0.0009568915,0.0011215],"domain_scores_gemma":[0.9952515,0.002303474,0.0005991618,0.001539809,0.0001832698,0.0001227638],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9837554,0.0008059473,0.001077916,0.00009774661,0.001032077,0.0008894567,0.0007312477,0.00004961528,0.0006383162,0.000004850874,0.01053794,0.0003794698],"study_design_scores_gemma":[0.9708475,0.008931994,0.01145317,0.0001232593,0.0009649051,0.000176064,0.00001774019,0.0001763017,0.00002045222,0.00001073912,0.006995928,0.0002818952],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6445071,0.0001860792,0.000002310539,0.3459833,0.0001867995,0.008987856,0.00002344776,0.00003234317,0.00009071672],"genre_scores_gemma":[0.8968145,0.0006099073,0.00001623554,0.09755447,0.002807735,0.001324021,0.0001346871,0.0001293671,0.0006090786],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2523074,"threshold_uncertainty_score":0.9999204,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08461749481689211,"score_gpt":0.3404554619137068,"score_spread":0.2558379670968147,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}